Publicação
Antiretroviral treatment of HIV-2 infection : available drugs, resistance pathways, and promising new compounds
| datacite.subject.fos | Ciências Médicas | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| dc.contributor.author | Moranguinho, Inês | |
| dc.contributor.author | Taveira, Nuno | |
| dc.contributor.author | Bártolo, Inês | |
| dc.date.accessioned | 2025-12-05T11:38:48Z | |
| dc.date.available | 2025-12-05T11:38:48Z | |
| dc.date.issued | 2023-03 | |
| dc.description.abstract | Currently, it is estimated that 1–2 million people worldwide are infected with HIV-2, accounting for 3–5% of the global burden of HIV. The course of HIV-2 infection is longer compared to HIV-1 infection, but without effective antiretroviral therapy (ART), a substantial proportion of infected patients will progress to AIDS and die. Antiretroviral drugs in clinical use were designed for HIV-1 and, unfortunately, some do not work as well, or do not work at all, for HIV-2. This is the case for non-nucleoside reverse transcriptase inhibitors (NNRTIs), the fusion inhibitor enfuvirtide (T-20), most protease inhibitors (PIs), the attachment inhibitor fostemsavir and most broadly neutralizing antibodies. Integrase inhibitors work well against HIV-2 and are included in first-line therapeutic regimens for HIV-2-infected patients. However, rapid emergence of drug resistance and cross-resistance within each drug class dramatically reduces second-line treatment options. New drugs are needed to treat infection with drug-resistant isolates. Here, we review the therapeutic armamentarium available to treat HIV-2-infected patients, as well as promising drugs in development. We also review HIV-2 drug resistance mutations and resistance pathways that develop in HIV-2-infected patients under treatment. | eng |
| dc.identifier.citation | Moranguinho I, Taveira N, Bártolo I. Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds. International Journal of Molecular Sciences. 2023; 24(6):5905. https://doi.org/10.3390/ijms24065905 | |
| dc.identifier.doi | 10.3390/ijms24065905 | |
| dc.identifier.issn | 1422-0067 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/60260 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | MDPI | |
| dc.relation.hasversion | https://doi.org/10.3390/ijms24065905 | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | HIV-2 | |
| dc.subject | HIV-2 treatment | |
| dc.subject | antiretroviral drugs | |
| dc.subject | resistance mutations | |
| dc.subject | resistance pathways | |
| dc.title | Antiretroviral treatment of HIV-2 infection : available drugs, resistance pathways, and promising new compounds | eng |
| dc.type | contribution to journal | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 6 | |
| oaire.citation.startPage | 5905 | |
| oaire.citation.title | International Journal of Molecular Sciences | |
| oaire.citation.volume | 24 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |